
Gennex Laboratories Ltd is Rated Sell
2026-11-18 10:11:06Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 November 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Gennex Laboratories Ltd is Rated Sell
2026-11-06 10:11:34Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 06 November 2026, providing investors with the most up-to-date view of the company’s performance and outlook.
Read More
Gennex Laboratories Ltd is Rated Sell
2026-10-26 10:10:26Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 26 October 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.
Read More
Gennex Laboratories Ltd is Rated Sell
2026-10-15 10:10:40Gennex Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 15 October 2026, providing investors with the latest insights into the company’s performance and outlook.
Read More
Gennex Laboratories Ltd is Rated Sell
2026-10-04 10:10:27Gennex Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 October 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Read More
Gennex Laboratories Ltd is Rated Sell
2026-09-23 10:10:46Gennex Laboratories Ltd is rated Sell by MarketsMOJO, with this rating last updated on 07 September 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 23 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trend, and technical outlook.
Read More
Gennex Laboratories Ltd Downgraded to Sell Amid Mixed Financial and Technical Signals
2026-09-08 09:02:34Gennex Laboratories Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 7 September 2026. This change reflects a combination of deteriorating technical indicators, flat recent financial performance, and concerns over promoter share pledging, despite attractive valuation metrics and long-term market-beating returns.
Read MoreGennex Laboratories Declines 6.12% Amid Valuation Reset and Technical Upgrade
2026-09-05 14:06:59Key Events This Week 31 Aug: Stock opens at ₹12.62, down 2.25% amid broader market weakness 1 Sep: Mojo grade upgraded to Hold on improved technicals and valuation 2-3 Sep: Continued price decline with subdued volumes 4 Sep: Price rebounds 2.71% to close at ₹12.12, Sensex gains 0.19% Week Open₹12.91 Week Close<div cla...
Read More
Gennex Laboratories Ltd Valuation Shifts Signal Renewed Price Attractiveness
2026-09-01 08:00:57Gennex Laboratories Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive grade, signalling a potential opportunity for investors in the Pharmaceuticals & Biotechnology sector. This re-rating comes amid a backdrop of mixed sector valuations and a micro-cap status that warrants close attention.
Read MoreAnnouncement under Regulation 30 (LODR)-Newspaper Publication
17-Nov-2026 | Source : BSEPursuant to regulation 47 of SEBI (LODR) Regulations 2015 please find enclosed herewith Newspaper publication on Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30 2026 announced by the Board of Directors in its meeting held on Saturday November 14 2026. Financial results had been published in both Business Standard (English) and Saksham (Telugu - Local) on November 17 2026.
Intimation Regarding Dissolution Of The Rights Issue Committee Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015
14-Nov-2026 | Source : BSEPursuant to Regulation 30 read with Schedule III of the SEBI (LODR) Regulations 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. November 14 2026 has approved the dissolution of the Rights Issue Committee with immediate effect i.e. November 14 2026.
Board Meeting Outcome for Meeting Held Today I.E. 30Th September 2026
14-Nov-2026 | Source : BSE1. Unaudited (Standalone and Consolidated) Financial Results for the Quarter and Half year ended September 30 2026 along with the Statement of Assets and Liabilities as at September 30 2026 and the Statement of Cash Flows for the half year ended September 30 2026 (annexed herewith);
Corporate Actions
No Upcoming Board Meetings
No Dividend history available
Gennex Laboratories Ltd has announced 1:10 stock split, ex-date: 14 Dec 09
No Bonus history available
Gennex Laboratories Ltd has announced 1:2 rights issue, ex-date: 21 Jul 22